2,3,5-trimethylhydroquinone

Acute Toxicity: other routes

Administrative data

Endpoint:

acute toxicity: other routes

Type of information:

experimental study

Adequacy of study:

other information

Reliability:

2 (reliable with restrictions)

Rationale for reliability incl. deficiencies:

other: Meets generally accepted scientific standards, well documented and acceptable for assessment; pre-GLP study.

Cross-reference

Reason / purpose for cross-reference:

reference to same study

Data source

Reference

Reference Type:

study report

Title:

Unnamed

Year:

1969

Report date:

1969

Materials and methods

Test guideline

Qualifier:

no guideline followed

Principles of method if other than guideline:

Internal BASF method was used

GLP compliance:

no

Limit test:

no

Test material

Test material information

Constituent 1

Reference substance name:

2,3,5-trimethylhydroquinone

EC Number:

211-838-3

EC Name:

2,3,5-trimethylhydroquinone

Cas Number:

700-13-0

Molecular formula:

C9H12O2

IUPAC Name:

2,3,5-trimethylbenzene-1,4-diol

Details on test material:

- Name of test material (as cited in study report): trimethylhydroquinone

Test animals

Species:

mouse

Strain:

not specified

Sex:

male/female

Details on test animals or test system and environmental conditions:

TEST ANIMALS
- Source: Kisslegg
- Weight at study initiation: mean 27.7 (male), 21.9 g (female)

Administration / exposure

Route of administration:

intraperitoneal

Vehicle:

other: aqueous suspension with Traganth

Details on exposure:

- Concentration in vehicle: 0.5, 1, 2, 16%

Doses:

50, 64, 80, 100, 200, 1600 mg/kg bw

No. of animals per sex per dose:

5

Control animals:

no

Details on study design:

- Duration of observation period following administration: 7days, except 14 days for 64 mg/kg bw dose group
- Frequency of observations and weighing: prior to study
- Necropsy of survivors performed: yes
- Other examinations performed: clinical signs

Results and discussion

Effect levels

Sex:

male/female

Dose descriptor:

LD50

Effect level:

ca. 65 mg/kg bw

Mortality:

1600 mg/kg bw: 10/10 animals within 1 h
200 mg/kg bw: 9/10 animals within 1 h; 10/10 animals within 7 days
100 mg/kg bw: 7/10 animals within 24 h; 8/10 animals within 48 h; 10/10 animals within 7 days
80 mg/kg bw: 4/10 animals within 24 h; 7/10 animals within 7 days
64 mg/kg bw: 1/10 animals within 24 h; 5/10 within 7 days; 6/10 animals within 14 days
50 mg/kg bw: no mortalities

Clinical signs:

200, 1600 mg/kg bw: Convulsions (saltatory convulsions, rolling fits, palmospasms, nodding spasms) dyspnea, morphinic tail, caynosis, and serous secretion from the buccal cavity was noted immediately after dosing
50, 64, 80, 100 mg/kg bw: Enhanced respiration, tremor, twitching, stretching, bending, abnormal gait, and partially morphinic tails was noted immediately after dosing. During the following days, squatting posture, irregular respiration, piloerection, adhesive eyes, and poor general state was observed.

Gross pathology:

In decedents, intrabdominal adhesions (2 mice), partially vascularized sections of the gut (1 mouse) and putrefaction was noted. Slight adhesions in the hepatic region was noted in all surviors sacrificed after the observation period.